Therapeutic Benefits of Induced Pluripotent Stem Cells in Monocrotaline-Induced Pulmonary Arterial Hypertension

Wei Chun Huang, Meng Wei Ke, Chin Chang Cheng, Shih Hwa Chiou, Shue Ren Wann, Chih Wen Shu, Kuan Rau Chiou, Ching Jiunn Tseng, Hung Wei Pan, Guang Yuan Mar, Chun Peng Liu

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Pulmonary arterial hypertension (PAH) is characterized by progressive increases in vascular resistance and the remodeling of pulmonary arteries. The accumulation of inflammatory cells in the lung and elevated levels of inflammatory cytokines in the bloodstream suggest that inflammation may play a role in PAH. In this study, the benefits of induced pluripotent stem cells (iPSCs) and iPSC-conditioned medium (iPSC CM) were explored in monocrotaline (MCT)-induced PAH rats. We demonstrated that both iPSCs and iPSC CM significantly reduced the right ventricular systolic pressure and ameliorated the hypertrophy of the right ventricle in MCT-induced PAH rats in models of both disease prevention and disease reversal. In the prevention of MCT-induced PAH, iPSC-based therapy led to the decreased accumulation of inflammatory cells and down-regulated the expression of the IL-1Aβ, IL-6, IL-12α, IL-12Aβ, IL-23 and IFNγ genes in lung specimens, which implied that iPSC-based therapy may be involved in the regulation of inflammation. NF-κB signaling is essential to the inflammatory cascade, which is activated via the phosphorylation of the NF-κB molecule. Using the chemical inhibitor specifically blocked the phosphorylation of NF-κB, and in vitro assays of cultured human M1 macrophages implied that the anti-inflammation effect of iPSC-based therapy may contribute to the disturbance of NF-κB activation. Here, we showed that iPSCbased therapy could restore the hemodynamic function of right ventricle with benefits for preventing the ongoing inflammation in the lungs of MCT-induced PAH rats by regulating NF-κB phosphorylation.

Original languageEnglish
Article numbere0142476
JournalPLoS One
Volume11
Issue number2
DOIs
Publication statusPublished - Feb 1 2016
Externally publishedYes

Fingerprint

monocrotaline
Monocrotaline
Induced Pluripotent Stem Cells
Stem cells
Pulmonary Hypertension
hypertension
lungs
therapeutics
Phosphorylation
Cell- and Tissue-Based Therapy
Rats
inflammation
Inflammation
phosphorylation
Therapeutics
Heart Ventricles
Cells
Interleukin-23
Lung
Macrophages

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Huang, W. C., Ke, M. W., Cheng, C. C., Chiou, S. H., Wann, S. R., Shu, C. W., ... Liu, C. P. (2016). Therapeutic Benefits of Induced Pluripotent Stem Cells in Monocrotaline-Induced Pulmonary Arterial Hypertension. PLoS One, 11(2), [e0142476]. https://doi.org/10.1371/journal.pone.0142476

Therapeutic Benefits of Induced Pluripotent Stem Cells in Monocrotaline-Induced Pulmonary Arterial Hypertension. / Huang, Wei Chun; Ke, Meng Wei; Cheng, Chin Chang; Chiou, Shih Hwa; Wann, Shue Ren; Shu, Chih Wen; Chiou, Kuan Rau; Tseng, Ching Jiunn; Pan, Hung Wei; Mar, Guang Yuan; Liu, Chun Peng.

In: PLoS One, Vol. 11, No. 2, e0142476, 01.02.2016.

Research output: Contribution to journalArticle

Huang, WC, Ke, MW, Cheng, CC, Chiou, SH, Wann, SR, Shu, CW, Chiou, KR, Tseng, CJ, Pan, HW, Mar, GY & Liu, CP 2016, 'Therapeutic Benefits of Induced Pluripotent Stem Cells in Monocrotaline-Induced Pulmonary Arterial Hypertension', PLoS One, vol. 11, no. 2, e0142476. https://doi.org/10.1371/journal.pone.0142476
Huang, Wei Chun ; Ke, Meng Wei ; Cheng, Chin Chang ; Chiou, Shih Hwa ; Wann, Shue Ren ; Shu, Chih Wen ; Chiou, Kuan Rau ; Tseng, Ching Jiunn ; Pan, Hung Wei ; Mar, Guang Yuan ; Liu, Chun Peng. / Therapeutic Benefits of Induced Pluripotent Stem Cells in Monocrotaline-Induced Pulmonary Arterial Hypertension. In: PLoS One. 2016 ; Vol. 11, No. 2.
@article{f731aaf69e974a3d8a8f05c6f3739acc,
title = "Therapeutic Benefits of Induced Pluripotent Stem Cells in Monocrotaline-Induced Pulmonary Arterial Hypertension",
abstract = "Pulmonary arterial hypertension (PAH) is characterized by progressive increases in vascular resistance and the remodeling of pulmonary arteries. The accumulation of inflammatory cells in the lung and elevated levels of inflammatory cytokines in the bloodstream suggest that inflammation may play a role in PAH. In this study, the benefits of induced pluripotent stem cells (iPSCs) and iPSC-conditioned medium (iPSC CM) were explored in monocrotaline (MCT)-induced PAH rats. We demonstrated that both iPSCs and iPSC CM significantly reduced the right ventricular systolic pressure and ameliorated the hypertrophy of the right ventricle in MCT-induced PAH rats in models of both disease prevention and disease reversal. In the prevention of MCT-induced PAH, iPSC-based therapy led to the decreased accumulation of inflammatory cells and down-regulated the expression of the IL-1Aβ, IL-6, IL-12α, IL-12Aβ, IL-23 and IFNγ genes in lung specimens, which implied that iPSC-based therapy may be involved in the regulation of inflammation. NF-κB signaling is essential to the inflammatory cascade, which is activated via the phosphorylation of the NF-κB molecule. Using the chemical inhibitor specifically blocked the phosphorylation of NF-κB, and in vitro assays of cultured human M1 macrophages implied that the anti-inflammation effect of iPSC-based therapy may contribute to the disturbance of NF-κB activation. Here, we showed that iPSCbased therapy could restore the hemodynamic function of right ventricle with benefits for preventing the ongoing inflammation in the lungs of MCT-induced PAH rats by regulating NF-κB phosphorylation.",
author = "Huang, {Wei Chun} and Ke, {Meng Wei} and Cheng, {Chin Chang} and Chiou, {Shih Hwa} and Wann, {Shue Ren} and Shu, {Chih Wen} and Chiou, {Kuan Rau} and Tseng, {Ching Jiunn} and Pan, {Hung Wei} and Mar, {Guang Yuan} and Liu, {Chun Peng}",
year = "2016",
month = "2",
day = "1",
doi = "10.1371/journal.pone.0142476",
language = "English",
volume = "11",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - Therapeutic Benefits of Induced Pluripotent Stem Cells in Monocrotaline-Induced Pulmonary Arterial Hypertension

AU - Huang, Wei Chun

AU - Ke, Meng Wei

AU - Cheng, Chin Chang

AU - Chiou, Shih Hwa

AU - Wann, Shue Ren

AU - Shu, Chih Wen

AU - Chiou, Kuan Rau

AU - Tseng, Ching Jiunn

AU - Pan, Hung Wei

AU - Mar, Guang Yuan

AU - Liu, Chun Peng

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Pulmonary arterial hypertension (PAH) is characterized by progressive increases in vascular resistance and the remodeling of pulmonary arteries. The accumulation of inflammatory cells in the lung and elevated levels of inflammatory cytokines in the bloodstream suggest that inflammation may play a role in PAH. In this study, the benefits of induced pluripotent stem cells (iPSCs) and iPSC-conditioned medium (iPSC CM) were explored in monocrotaline (MCT)-induced PAH rats. We demonstrated that both iPSCs and iPSC CM significantly reduced the right ventricular systolic pressure and ameliorated the hypertrophy of the right ventricle in MCT-induced PAH rats in models of both disease prevention and disease reversal. In the prevention of MCT-induced PAH, iPSC-based therapy led to the decreased accumulation of inflammatory cells and down-regulated the expression of the IL-1Aβ, IL-6, IL-12α, IL-12Aβ, IL-23 and IFNγ genes in lung specimens, which implied that iPSC-based therapy may be involved in the regulation of inflammation. NF-κB signaling is essential to the inflammatory cascade, which is activated via the phosphorylation of the NF-κB molecule. Using the chemical inhibitor specifically blocked the phosphorylation of NF-κB, and in vitro assays of cultured human M1 macrophages implied that the anti-inflammation effect of iPSC-based therapy may contribute to the disturbance of NF-κB activation. Here, we showed that iPSCbased therapy could restore the hemodynamic function of right ventricle with benefits for preventing the ongoing inflammation in the lungs of MCT-induced PAH rats by regulating NF-κB phosphorylation.

AB - Pulmonary arterial hypertension (PAH) is characterized by progressive increases in vascular resistance and the remodeling of pulmonary arteries. The accumulation of inflammatory cells in the lung and elevated levels of inflammatory cytokines in the bloodstream suggest that inflammation may play a role in PAH. In this study, the benefits of induced pluripotent stem cells (iPSCs) and iPSC-conditioned medium (iPSC CM) were explored in monocrotaline (MCT)-induced PAH rats. We demonstrated that both iPSCs and iPSC CM significantly reduced the right ventricular systolic pressure and ameliorated the hypertrophy of the right ventricle in MCT-induced PAH rats in models of both disease prevention and disease reversal. In the prevention of MCT-induced PAH, iPSC-based therapy led to the decreased accumulation of inflammatory cells and down-regulated the expression of the IL-1Aβ, IL-6, IL-12α, IL-12Aβ, IL-23 and IFNγ genes in lung specimens, which implied that iPSC-based therapy may be involved in the regulation of inflammation. NF-κB signaling is essential to the inflammatory cascade, which is activated via the phosphorylation of the NF-κB molecule. Using the chemical inhibitor specifically blocked the phosphorylation of NF-κB, and in vitro assays of cultured human M1 macrophages implied that the anti-inflammation effect of iPSC-based therapy may contribute to the disturbance of NF-κB activation. Here, we showed that iPSCbased therapy could restore the hemodynamic function of right ventricle with benefits for preventing the ongoing inflammation in the lungs of MCT-induced PAH rats by regulating NF-κB phosphorylation.

UR - http://www.scopus.com/inward/record.url?scp=84959017378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959017378&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0142476

DO - 10.1371/journal.pone.0142476

M3 - Article

C2 - 26840075

AN - SCOPUS:84959017378

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e0142476

ER -